by Noah Blaine

Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis

INDIANAPOLIS , Aug. 23, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal …

source https://finance.yahoo.com/news/lilly-announces-top-line-phase-185500237.html?.tsrc=rss

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.